Evidence map›Paper›PMID 42634683›Full record

ArticleJournal of inflammation research2026

Peripheral Blood Biomarkers for Predicting the Efficacy of Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.

Yuanyuan Shen, Jinnan Wang, Ruimeng Wang, Zhiqiang Liu, Yueyin Pan, Yingying Du, Menghao Dong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuanyuan ShenDepartment of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Jinnan WangEndoscopy Centre, Anhui Chest Hospital, Hefei, Anhui, People's Republic of China.
Ruimeng WangDepartment of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Zhiqiang LiuDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Yueyin PanDepartment of Clinical Oncology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
Yingying DuDepartment of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Menghao DongDepartment of Clinical Oncology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.ORCID 0009-0004-5719-5360

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to evaluate pre- and intra-treatment peripheral blood inflammatory and cellular indicators as predictors of pathological response to neoadjuvant immunotherapy plus chemotherapy (nICT) in locally advanced esophageal squamous cell carcinoma (ESCC), and their correlation with prognosis. Methods: 310 patients with locally advanced ESCC who received nICT plus radical surgery (Jan 2020-Dec 2025) were retrospectively divided into the pathological complete response (pCR) (n=63) and non-pCR (n=247) groups. Blood indicators at baseline, post-cycle 1, and pre-surgery were analyzed. Univariate and multivariate logistic regression identified independent predictors of response. Receiver operating characteristic curves assessed predictive efficacy and recurrence associations. Results: Overall pCR rate was 20.32% (63/310). Univariate analysis showed baseline (L Conclusion: nICT induces favorable pathological responses in locally advanced ESCC. Post-cycle lymphocyte count was associated with treatment response and recurrence risk, while elevated D-dimer

Indexed as

D-dimeresophageal squamous cell carcinomalymphocyte countneoadjuvant immunotherapypathological complete response

Identifiers

PMID42634683
PMCPMC13500025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.